Article

Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers

Author(s):

Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.

Shanu Modi, MD

Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers who previously received ado-trastuzumab emtansine (T-DM1; Kadcyla).

In an ongoing 2-part phase I study, the overall response rate (ORR) to trastuzumab deruxtecan in 57 evaluable patients with HER2-positive tumors was 61.4%. In 19 evaluable patients with HER2-low tumors, the median progression-free survival (PFS) had not yet been reached and the ORR was 31.6%, reported Shanu Modi, MD, at the 2017 San Antonio Breast Cancer Symposium.

In August 2017, trastuzumab deruxtecan received an FDA breakthrough therapy designation for the treatment of patients with HER2-positive, locally advanced, or metastatic breast cancer who have been treated with trastuzumab (Herceptin) and pertuzumab (Perjeta) and have disease progression after T-DM1.

Whereas T-DM1 is a tubulin-targeting chemotherapy, trastuzumab deruxtecan is a topoisomerase 1 inhibitor. It is highly potent, with a drug-to-antibody ratio of 7.8, compared with 3.5 for T-DM1, said Modi, a breast medical oncologist at Memorial Sloan Kettering Cancer Center.

“Overall, we’re happy to report that this is a really active drug,” she said. The 60% confirmed rate “is in patients who had some of the most potent HER2-targeted therapies already. It’s pretty exciting to see that kind of result. More importantly, is how durable the benefit is.” The Median PFS in the HER2-positive cohort was 10.4 months.

The study was conducted in 2 parts. In part 1, a modified continuous reassessment method was used to identify an expansion dose in patients with breast or gastric cancer. Based on part 1 results, doses of 5.4 and 6.4 mg/kg administered every 3 weeks were selected for part 2, which was designed to evaluate the safety and efficacy in 4 expansion cohorts: HER2-positive breast cancer previously treated with T-DM1, HER2-positive gastric cancer treated with trastuzumab, low-HER2—expressing breast cancer, and other HER2-expressing solid tumors. Modi’s presentation at SABCS focused on the 130 patients with breast cancer, 96 with HER2-positive tumors and 34 with low expression of HER2.

In the HER2-positive cohort, the ORR was 56.4% (22 of 39) among those with hormone receptor (HR)-positive disease and 75.0% (12 of 16) in those with HR-negative disease. Notably, the ORR was 62.5% among the 50 patients in this cohort with prior pertuzumab treatment.

The disease control rate (DCR) was 94.7% overall in the HER2-positive subset: 92.3% in the HR-positive group, 100.0% in the HR-negative group, and 94.0% among those who had received prior pertuzumab. “The responses were durable regardless of HR status,” said Modi. Median PFS was not yet reached in the HR-positive group and was 10.3 months in the HR-negative group. Median PFS was 10.3 months in the HER2-positive cohort who had received prior pertuzumab.

In the HER2-low cohort, 6 of 19 patients (31.6%) had a response, including 5 of 16 patients (31.3%) with HR-positive tumors. In the HER2-low subset, the DCR was 84.2%. By hormone receptor status, the DCR was 14 of 16 (87.5%) in those with HR-positive disease and 1 of 2 (50%) in patients with HR-negative disease. Median PFS was not reached in the HR-positive subset and was 7.6 months in the HR-negative group.

“These patients can stay on therapy for a long time,” said Modi. “We have some patients who are now up to a year and a half maintaining their response.”

The main toxicity was grade 1/2 gastrointestinal toxicity, which was “very manageable,” she said. Grade 1/2 nausea was reported by 67.9%. Grade 3 and 4 events were hematologic in nature. The rates of grade 3/4 anemia were 8.7% in the HER2-positive group and 0.9% in the HER2-low group. The rates of grade 3 decreases in neutrophil count and white blood cell count were each 10.4%. Across the study, 5 patients (4.3%) had a grade 4 decrease in neutrophil count.

An ongoing pivotal phase II trial called DESTINY-Breast01 is examining the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive unresectable and/or metastatic breast cancer who are resistant or refractory to T-DM1.

Modi S, Tsurutani J, Takahashi S, et al. Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. Abstract PD3-07.

Related Videos
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
John M. Burke, MD
Eunice S. Wang, MD
Rachel E. Rau, MD
Timothy S. Fenske, MD, MS
Dasom (Caroline) Lee, MD
Christina Poh, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
C. Ola Landgren, MD, PhD